Mood Disorders Psychopharmacology Unit

"We are an academic mood disorders research centre, providing leadership in translational research and novel opportunity treatment worldwide" #BehindTheLabel

[Mood Disorders Psychopharmacology Unit @MDPU_TWH]

Are you a healthy individual interested in clinical research? We're currently recruiting healthy participants for a clinical trial at Toronto Western Hospital. For more details, please contact us at [email protected] or 416-603-5800 (ext. 5633).

[Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat]

See our report on the Antidepressant Effects of #Psilocybin in the Absence of #Psychedelic Effects @APAPubJournals

We present the first in-human evidence to support antidepressant effects of psilocybin independent of 5HT2A and psychedelic effects

1/4

https://t.co/Wfoa9MexUt

[Danica Johnson (she/her) @DanicaEJohnson]

Very excited about my first first-author publication! I’m grateful to be part of such an amazing lab. Many thanks to my supervisor @JD_Rosenblat for his continued support and mentorship.

[Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat]

Congratulations to Danica Johnson @MDPU_TWH @UofTPsych:

An update on potential pharmacotherapies for cognitive impairment in bipolar disorder

FYI Danica is studying the effect of #ketamine and #psilocybin on cognitive function so more to come!

https://t.co/EaeLp3tu5Q

[Roger S. McIntyre, MD, FRCPC @rogersmcintyre]

Very interesting case lead by Dr Josh Rosenblat from our team that the use of a 5HTA antagonist with psilocybin did not attenuate antidepressant effect in TRD raises interesting conceptual questions on mechanisms of psilocybin effects . https://t.co/XUAroi268m

[Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat]

Congrats Dr Lee @MDPU_TWH @UHN_Research @UofTPsych on another great paper

Association of a low protein diet with depressive symptoms and poor health-related quality of life in CKD

50 day free full text Link:
https://t.co/0qwIibbUdC

[Mood Disorders Psychopharmacology Unit @MDPU_TWH]

Do you have a clinical diagnosis of Major Depressive Disorder or Bipolar Disorder? We're currently recruiting participants for a clinical trial at Toronto Western Hospital. For more details, please contact us at [email protected] or 416-603-5800 (ext. 5633).

[Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat]

Real World Effectiveness of Repeated #Ketamine Infusions for Treatment-Resistant #Depression with Comorbid #Borderline Personality Disorder

50 days #free access to full text:

https://t.co/Ayz29mcQZX

[Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat]

Congrats to our excellent summer student Kevork @UofTPsych on this important analysis:

Effectiveness of #Ketamine for Treatment-Resistant Depression with Comorbid Borderline Personality Disorder (BDP)

Ketamine reduced symptoms of both BPD + Depression

https://t.co/XgEM7pVGZU

[Brain and Cognition Discovery Foundation (BCDF) @BCDFoundation]

Congratulations to our very own Dr. @rogersmcintyre, the Chairman & Executive Director of the @BCDFoundation, and all the other @UHN researchers who have made the 2022 list of Highly Cited Researchers from @Clarivate! 👏

https://t.co/0D4LzChC6h

@MDPU_TWH @UofTPsych #research

[Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat]

⁦@MDPU_TWH⁩ representing ⁦@CPA_APC⁩ !

[Shakila Meshkat @shakilameshkat]

Happy to see our article published in Psychiatry Research.

I am grateful to @JD_Rosenblat for their insightful supervision on this project and for all the help and support.

https://t.co/zjrj0UdEcy

[Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat]

Great to see all the wonderful work happening @UofTPsych this year. Also grateful for our #psilocybin research to be featured in the Annual Report.

Advancing Treatments in Psychiatry https://t.co/Fnoqsd1VXY

[Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat]

Huge congrats to Anastasia Levinta, a talented resident @UofTPsych who did an elective with @MDPU_TWH last year & wrote this important report:

The association between stage of treatment-resistant #depression & clinical utility of #ketamine

50d #free FT
https://t.co/p7e5FNctvd

[Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat]

See our national @CANMAT_org guidelines on #psychedelics out today @TheCJPsych

We hope this report will provide a helpful summary and guidance for clinicians, researchers, patients, regulators and stakeholders. 1/3

https://t.co/YJAyP9S7Bi

[Roger S. McIntyre, MD, FRCPC @rogersmcintyre]

Congratulations to Dr. Josh Rosenblat in leading the team on this very important campaign On behalf of CANMAT providing guidelines for psychedelics the first such guideline globally! https://t.co/Kp5Oed4dF0

[Youshay Jawad @youshayjwd]

I am excited to have a public discussion around loneliness with my mentor @rogersmcintyre. Loneliness is just as dangerous as any other physical or mental ailment and can have far-reaching health consequences.
🔗 For twitter space. Join to get a reminder! https://t.co/JrEViXCeS9

[Mood Disorders Psychopharmacology Unit @MDPU_TWH]

Read our latest publication about Active mechanisms of ketamine-assisted psychotherapy: A systematic review🔻 #psychotherapy #mentalhealthishealth ⁦@UofT⁩ ⁦@UofTPsych⁩ https://t.co/i4i1a2U1Dd

[Mood Disorders Psychopharmacology Unit @MDPU_TWH]

New paper alert🚨#Psychiatry #ketamine #psychotherapy

[Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat]

Congrats on an excellent paper, Isak! Isak also did a great job helping us launch our psilocybin trail last year @braxiahq

Active mechanisms of #ketamine-assisted psychotherapy: A systematic review

50 days' free full text:
https://t.co/QWVRB7vjL6

[Shakila Meshkat @shakilameshkat]

I’m happy to be a part of this excellent paper by Isak. Read our latest review about active mechanisms of #ketamine assisted #psychotherapy.

https://t.co/UVK33T5ScG